Notice of Results

RNS Number : 4612O
Oxford Biomedica PLC
07 August 2014
 



Oxford BioMedica: Notice of Interim Results

Results date: 28 August 2014

 

 

Oxford, UK - 7 August 2014: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the Company") a leading gene- and cell-therapy company, will be announcing its interim results for the six months ended 30 June 2014 on Thursday, 28 August 2014.

 

An analyst briefing will be held at 09:30am GMT on Thursday, 28 August 2014 at the offices of Consilium Strategic Communications, 41 Lothbury, London, EC2R 7HG.  An audio replay will be made available shortly after the presentation on the Company's website: www.oxfordbiomedica.co.uk.

 

-Ends-

 

For further information, please contact:

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

Tel: +44 (0)1865 783 000

 

Media Enquiries:

Mary-Jane Elliott/Emma Thompson/Matthew Neal

Consilium Strategic Communications

 

 

Tel: +44 (0)20 3709 5700

 

Notes to editors

 

About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.  Through in-house and collaborative research, Oxford BioMedica has a broad range of partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

NORZMGGRKVLGDZM